Further into the future, patients suffering from any type of virus could be cured with DRACO
Newly emerging flu viruses could soon be countered by a treatment that Draper Laboratory is developing that “traps” viruses before they can infect host cells.
Further into the future, patients suffering from any type of virus could be cured with DRACO, a drug also under development at Draper that is designed to rapidly recognize and eliminate cells infected by virtually any virus.
Both methods could help safeguard against bioterrorist attacks and naturally occurring pandemics in a manner that is unlikely to lead to treatment-resistant strains. Initial testing on the treatments, which each use tiny, non-toxic particles that can be injected, inhaled, or eaten, has shown them to be effective and safe against a multitude of strains of disease.
Nanotraps, which could be taken at the first sign of infection or exposure, is likely the first of the products ready for use, and is expected to begin clinical trials in two to five years, according to Jim Comolli, who leads the research on the effort at Draper.
Nanotraps, developed by a team of researchers from Draper, MIT, the University of Massachusetts Medical School, and the University of Santa Barbara, are nanoparticles that act as viral “traps” using specific molecules found naturally within the human body. A paper published in the March issue of Journal of Biological Chemistry detailed their findings.
The nanotraps look like the surface of a cell, with numerous carbohydrate molecules attached that closely resemble those targeted by flu viruses in the human respiratory system. These molecules, initially characterized in the Sasisekharan Lab at MIT, act as bait for the flu virus, which bind to the nanotrap instead of a host cell and are cleared away with mucus, preventing infection, Comolli said.
The research team has demonstrated in the laboratory that the nanotraps effectively countered multiple influenza strains able to infect humans and went on to show nanotraps protected mice infected with the flu. They have also developed additional particles geared toward other types of respiratory viruses.
Nanotraps, unlike most vaccines, are not strain specific and are designed to be effective against newly emerging strains of human-adapted influenza virus. Since nanotraps mimic a fundamental step in the viral life cycle – the binding of the virus to a host cell’s receptor – nanotraps may offer an opportunity to treat devastating infectious diseases without causing the development of treatment resistance, Comolli said.
The nanotrap molecule is composed mainly of compounds found naturally in the human body so it is likely to be safe as an inhalant, topical solution, or intravenous treatment and inexpensive to manufacture. With further development, nanotraps have the potential to treat a large range of infectious diseases because the attached carbohydrates can be tuned for other viruses such as HIV, Respiratory Syncytial Virus (RSV), and Herpes Simplex Virus (HSV), as well as bacteria and toxins.
The work was originally funded by the Defense Advanced Research Projects Agency (DARPA) to address emerging pandemics or bioweapons targeting US troops; Draper is continuing the research with the intent of applying it more broadly to the civilian community.
While nanotraps could be customized to treat a variety of viruses, another project underway at Draper, DRACO could do so with a single approach. DRACO is a unique therapeutic drug that should be effective against a very broad spectrum of viruses, just as existing antibiotics are effective against a broad range of bacterial infections. DRACO could be ready for human clinical trials in five to 10 years, according to Todd Rider, who leads the research at Draper.
DRACO (Double-stranded RNA Activated Caspase Oligomerizer) is designed to detect cells that have been virally infected and then eradicate only the infected cells, rapidly ending the infection. DRACO has proven effective in vivo against influenza and three hemorrhagic fever viruses, and in vitro against 15 different viruses – including common cold viruses, the H1N1 influenza strain, adenoviruses, a mouse polio virus, dengue fever, and stomach viruses, among others. It has also been tested and proven safe in both mice and 11 different human and animal cell types representing organs like the heart, lungs, liver, and kidney, among others.
DRACO is designed to be attracted to a specific type of RNA exclusive to viral infections – long double-stranded RNA, or dsRNA. Detecting this dsRNA in a human or animal cell indicates that that host cell has been taken over by a virus and is now in the process of creating more viruses. DRACO enters cells and attaches itself to any dsRNA. Once two or more DRACOs attach to the dsRNA, they interact with one another and activate a natural self-destruct switch inside the infected cell, terminating the infected cell and the virus that it was helping to reproduce.
The Latest on: Viral infections
via Google News
The Latest on: Viral infections
- The corona lexicon: Super spreader to viral load and social- distancingon April 1, 2020 at 4:48 am
Flattening the curve refers to using protective practices to slow the rate of covid-19 infection so that hospitals have room ... The suggests that bats might have been a host of the novel coronavirus.
- Unraveling a coronavirus mystery: Stomach bug can be sign of infectionon April 1, 2020 at 4:29 am
UCI warns clinicians to be on the lookout, pointing to patient who had traveled from California to Utah and back while ill.
- Coronavirus Pandemic: Ministry of AYUSH Suggests Immunity Boosting Practices to Reduce Risk of Getting The Infectionon March 31, 2020 at 8:23 pm
In the wake of the ongoing pandemic, coronavirus, India’s Ministry of AYUSH has recently released a list of Ayurveda practices that you can adopt and reduce your likelihood of getting the novel viral ...
- Phage capsid against influenza: Perfectly fitting inhibitor prevents viral infectionon March 31, 2020 at 4:36 am
Current antiviral drugs are only partially effective because they attack the influenza virus after lung cells have been infected. It would be desirable—and much more effective—to prevent infection in ...
- Not all viral diseases are contagious: Know the viruses that spread from person to personon March 29, 2020 at 7:16 am
Viruses are microscopic organisms that are available abundantly on the earth. They consist of genetic material, RNA or DNA, surrounded by a coat of protein, lipid (fat), or glycoprotein. As viruses ...
- Physically Speaking: Recovering from viral illness and infectionson March 29, 2020 at 2:50 am
- Worldwide viral infections top 500,000 as economic toll riseson March 26, 2020 at 10:55 am
The number of coronavirus infections closed in on a half-million worldwide Thursday, with both Italy and the U.S. on track to surpass China, and a record-shattering 3.3 million Americans applied for ...
- Scientists propose reliable viral labeling strategy for visualization of EV71 infectionon March 26, 2020 at 8:23 am
Although genetic engineering and chemical coupling have been applied to track viral infection in host cells and in vivo, these strategies could potentially interfere with viral invasive pathways. The ...
- Antiviral Booster Drugs Market: Increase in Incidence Rate of Viral Infectious Diseases to Drive Growthon March 26, 2020 at 5:48 am
Most of the antiviral drugs are used in the treatment of infections caused by a specific virus; however, broad spectrum antiviral drugs are effective against a wide range of viral infections. Most of ...
- Pharmaceutical Development Ramp up as Viral Infections Continue to Threatenon March 24, 2020 at 6:00 am
/PRNewswire/ -- The global pharmaceutical contract development and manufacturing industry is driven by various major factors; these include the rising demand ...
via Bing News